ArticleFrontiers in surgery2026
V3 midface lifting through a subciliary approach: a three-vector physiologic repositioning technique for midface rejuvenation, lower eyelid support, and lower lid-malar contour improvement.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Conventional midface rejuvenation through temporal or preauricular incisions often fails to adequately restore the central midface and tear trough vector. We describe the "V3 midface lift"-a transcutaneous subciliary technique utilizing a three-vector physiologic repositioning system to address midface ptosis, lower eyelid bags, and lower lid-malar contour disharmony. Methods: A consecutive cohort of 42 patients (38 females, 4 males; mean age: 46.2 ± 6.8 years) who underwent the V3 midface lift between January 2022 and December 2024 was retrospectively analyzed. The technique incorporates an extended subciliary incision, selective orbicularis oculi release, conservative septal fat management, and multi-point periosteal/fascial suspension anchored along three specific vectors: the medial canthal line, lateral canthal line, and the inferior boundary of the malar fat pad (adjacent to the melolabial fold). Quantitative outcomes were assessed using pre- and postoperative lower lid-malar distance (LMD), tear trough rating scales, and the Global Aesthetic Improvement Scale (GAIS). Results: All 42 patients completed follow-ups ranging from 12 to 36 months (mean: 22.4 months). Significant reductions in lower lid-malar distance (mean reduction: 3.4 ± 0.8 mm, Conclusions: The V3 midface lift provides safe, stable, and durable midface elevation and lower lid-malar continuity through a minimalist subciliary access, representing an efficient option for central facial rejuvenation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.